<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02190292</url>
  </required_header>
  <id_info>
    <org_study_id>523-2011-3646_1</org_study_id>
    <nct_id>NCT02190292</nct_id>
  </id_info>
  <brief_title>PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      Background: Obsessive-compulsive disorder (OCD) is considered one of the most debilitating of
      the psychiatric illnesses, yet much remains unclear regarding causes and cures. A diagnostic
      subgroup with acute onset of obsessive-compulsive symptoms (and sometimes tics or anorexia
      nervosa) possibly due to an autoimmune response, has been entitled Pediatric Acute onset
      Neuropsychiatric Syndrome (PANS). PANS is sometimes treated with immunomodulatory therapy or
      antibiotics, with a variable outcome. A diagnosis of PANS is supported by elevated levels of
      auto-antibodies and antibody-enzyme activity measured with the Cunningham panel, but the
      relationship between these biomarkers and the patients' symptoms remains unclear. A clinician
      rated symptom scale for PANS (the PANS scale) has been developed, but needs to be further
      evaluated regarding sensitivity and specificity.

      Aims:

        -  To assess a Swedish cohort of patients diagnosed with PANS and compile their psychiatric
           health status, biomarkers, psychiatric symptoms, soft neurological signs and treatment
           outcomes in a systematic way

        -  To compare psychiatric health status, biomarkers and psychiatric, neurologic and motor
           symptoms in this PANS cohort with a control group of psychiatric patients and with
           healthy children.

        -  To evaluate the Cunningham panel as a diagnostic tool for PANS.

        -  To evaluate a clinician rated symptom scale (the PANS scale) as a diagnostic tool for
           PANS.

      Method: Observational study Participants: Patients (n≈150) who have been tested with the
      Cunningham panel of PANS biomarkers in Sweden (or Swedish patients tested in Denmark) will be
      asked to participate.

      Procedure: Assessment of current symptoms, psychiatric health, neurological and motor
      symptoms and possible biomarkers for PANS will be collected for all patients. Retrospective
      assessment through interview and medical records, including results from the first assessment
      with the Cunningham panel of PANS-biomarkers is made with all patients. 50 out of the total
      PANS cohort of 150 patients will be re-tested with the Cunningham panel. A control group
      consisting of psychiatric patients (n=60) and healthy children (n=25) will be examined with a
      similar test battery and signs and symptoms will be compared with the PANS group.

      Significance:

      Previous and current symptoms of PANS, levels of PANS biomarkers and treatment outcome will
      be investigated, thus knowledge regarding long-term outcome and evidence for the use of
      clinical assessment tools and biomarkers for diagnosing PANS will be gained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collected comprises:

      Retrospective data

        -  Interview

        -  Medical records

        -  Five to Fifteen (FTF)

        -  Cunningham panel of PANS biomarkers result prior to inclusion (at time point 1)

        -  Change in Clinical Global Impression-Improvement (CGI-I) since the first assessment of
           the Cunningham panel

      Current data

      Current levels of Cunningham panel of PANS biomarkers

      • Cunningham panel of PANS biomarkers at time point 2

      Current neuropsychiatric status

        -  Psychiatric interview

        -  PANS symptom scale

      Standardized assessment for children:

        -  Child behavior checklist (CBCL)

        -  The Autism spectrum Quotient: Children's version (AQ-Child)

        -  Brief Obsessive-Compulsive Scale (BOCS)

        -  Mini international Neuropsychiatric Interview - KID (M.I.N.I. KID)

        -  Five to Fifteen (FTF)

      Standardized assessment for adults:

        -  Schizotypal Personality Disorder Questionnaire (SPQ)

        -  Liebowitz social anxiety scale (LSAS)

        -  The Autism spectrum Quotient (AQ)

        -  Adult ADHD Self-Report Scale (ASRS)

        -  Brown Attention-Deficit Disorder Scales (Brown ADD Scales)

        -  Quality of Life Inventory (QOLI)

        -  Brief obsessive-compulsive scale (BOCS)

        -  Mini international Neuropsychiatric Interview (M.I.N.I.)

        -  FTF retrospective data

      Current soft neurological signs

        -  Alternating skips

        -  Romberg's balance test

        -  Diadochokinesia

        -  Involuntary finger movements

      Current neuropsychological status

        -  Drawing exercises

        -  Writing exercises

        -  WAIS/WISC Block design

        -  WAIS/WISC Digit Span

        -  WAIS/WISC Letter Number Sequencing

        -  WAIS/WISC Digit Symbol Coding

      Current biomarkers in blood/serum

        -  D8/17 antigen expression

        -  Human leukocyte antigen (HLA)

        -  C-reactive protein (CRP)

        -  T-cell activation

        -  Human proteome serum analysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychiatric health of individuals assessed with the Cunningham Panel of PANS-biomarkers</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of the Cuningham-Panel of PANS biomarkers as a diagnostic tool for PANS</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Obsessive-compulsive Disorder With Acute Onset</condition>
  <condition>PANDAS</condition>
  <condition>Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections</condition>
  <condition>Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)</condition>
  <condition>Childhood Acute Neuropsychiatric Symptoms (CANS)</condition>
  <condition>Obsessive-compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>PANS group</arm_group_label>
    <description>All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychiatric controls</arm_group_label>
    <description>60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>25 age and sex matched children to the PANS group will be recruited.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood (whole blood and serum)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive cases that have been assumed to have PANS and have been assessed with the
        Cunningham panel in Scandinavia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria the PANS-group:

          -  Scandinavian patients assessed with the Cunningham panel through Wieslab, Lund, Sweden
             or Statens Serum Institut (SSI), Copenhagen, Denmark.

        Exclusion Criteria PANS-group:

          -  intellectual disability, non-Swedish speaking

        Inclusion Criteria Psychiatric Controls:

          -  diagnosed with a psychiatric disorder

          -  age &lt;40 years

        Exclusion Criteria Psychiatric Controls:

          -  intellectual disability, non-Swedish speaking

        Inclusion Criteria Healthy Controls:

          -  age and sex matched to the PANS-group

        Exclusion Criteria Healthy controls:

          -  intellectual disability, non-Swedish speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Northern Stockholm psychiatry</name>
      <address>
        <city>Stockholm</city>
        <state>Sverige</state>
        <zip>SE-112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bejerot S, Bruno K, Gerland G, Lindquist L, Nordin V, Pelling H, Humble MB. [Suspect PANDAS in children with acute neuropsychiatric symptoms. Infection behind the disease - long-term antibiotic therapy should be considered]. Lakartidningen. 2013 Oct 9-15;110(41):1803-6. Review. Swedish.</citation>
    <PMID>24187894</PMID>
  </reference>
  <reference>
    <citation>Bernstein GA, Victor AM, Pipal AJ, Williams KA. Comparison of clinical characteristics of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):333-40. doi: 10.1089/cap.2010.0034.</citation>
    <PMID>20807071</PMID>
  </reference>
  <reference>
    <citation>Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, Winter C, Klein J, Moses AE, Somnier FE, Leckman JF, Swedo SE, Cunningham MW, Joel D. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012 Aug;37(9):2076-87. doi: 10.1038/npp.2012.56. Epub 2012 Apr 25.</citation>
    <PMID>22534626</PMID>
  </reference>
  <reference>
    <citation>Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol. 2007 May;22(5):550-4.</citation>
    <PMID>17690060</PMID>
  </reference>
  <reference>
    <citation>Hachiya Y, Miyata R, Tanuma N, Hongou K, Tanaka K, Shimoda K, Kanda S, Hoshino A, Hanafusa Y, Kumada S, Kurihara E, Hayashi M. Autoimmune neurological disorders associated with group-A beta-hemolytic streptococcal infection. Brain Dev. 2013 Aug;35(7):670-4. doi: 10.1016/j.braindev.2012.10.003. Epub 2012 Nov 9.</citation>
    <PMID>23142103</PMID>
  </reference>
  <reference>
    <citation>Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003 Jul;9(7):914-20.</citation>
    <PMID>12819778</PMID>
  </reference>
  <reference>
    <citation>Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol. 2006 Oct;179(1-2):173-9. Epub 2006 Jul 27.</citation>
    <PMID>16875742</PMID>
  </reference>
  <reference>
    <citation>Kurlan R, Johnson D, Kaplan EL; Tourette Syndrome Study Group. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics. 2008 Jun;121(6):1188-97. doi: 10.1542/peds.2007-2657.</citation>
    <PMID>18519489</PMID>
  </reference>
  <reference>
    <citation>Leckman JF, King RA, Gilbert DL, Coffey BJ, Singer HS, Dure LS 4th, Grantz H, Katsovich L, Lin H, Lombroso PJ, Kawikova I, Johnson DR, Kurlan RM, Kaplan EL. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):108-118.e3. doi: 10.1016/j.jaac.2010.10.011. Epub 2010 Dec 31.</citation>
    <PMID>21241948</PMID>
  </reference>
  <reference>
    <citation>Leonard HL, Swedo SE. Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). Int J Neuropsychopharmacol. 2001 Jun;4(2):191-8.</citation>
    <PMID>11466169</PMID>
  </reference>
  <reference>
    <citation>Mabrouk AA, Eapen V. Challenges in the identification and treatment of PANDAS: a case series. J Trop Pediatr. 2009 Feb;55(1):46-8. doi: 10.1093/tropej/fmn039. Epub 2008 May 22.</citation>
    <PMID>18499734</PMID>
  </reference>
  <reference>
    <citation>Morris-Berry CM, Pollard M, Gao S, Thompson C; Tourette Syndrome Study Group, Singer HS. Anti-streptococcal, tubulin, and dopamine receptor 2 antibodies in children with PANDAS and Tourette syndrome: single-point and longitudinal assessments. J Neuroimmunol. 2013 Nov 15;264(1-2):106-13. doi: 10.1016/j.jneuroim.2013.09.010. Epub 2013 Sep 18.</citation>
    <PMID>24080310</PMID>
  </reference>
  <reference>
    <citation>Murphy TK, Goodman WK, Fudge MW, Williams RC Jr, Ayoub EM, Dalal M, Lewis MH, Zabriskie JB. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry. 1997 Mar;154(3):402-7.</citation>
    <PMID>9054790</PMID>
  </reference>
  <reference>
    <citation>Murphy TK, Kurlan R, Leckman J. The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):317-31. doi: 10.1089/cap.2010.0043. Review.</citation>
    <PMID>20807070</PMID>
  </reference>
  <reference>
    <citation>Murphy TK, Sajid M, Soto O, Shapira N, Edge P, Yang M, Lewis MH, Goodman WK. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol Psychiatry. 2004 Jan 1;55(1):61-8.</citation>
    <PMID>14706426</PMID>
  </reference>
  <reference>
    <citation>Nicholson TR, Ferdinando S, Krishnaiah RB, Anhoury S, Lennox BR, Mataix-Cols D, Cleare A, Veale DM, Drummond LM, Fineberg NA, Church AJ, Giovannoni G, Heyman I. Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. Br J Psychiatry. 2012 May;200(5):381-6. doi: 10.1192/bjp.bp.111.092007. Epub 2012 Jan 26.</citation>
    <PMID>22282431</PMID>
  </reference>
  <reference>
    <citation>Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999 Oct 2;354(9185):1153-8.</citation>
    <PMID>10513708</PMID>
  </reference>
  <reference>
    <citation>Singer HS, Gilbert DL, Wolf DS, Mink JW, Kurlan R. Moving from PANDAS to CANS. J Pediatr. 2012 May;160(5):725-31. doi: 10.1016/j.jpeds.2011.11.040. Epub 2011 Dec 22. Review. Erratum in: J Pediatr. 2012 May;160(5):888.</citation>
    <PMID>22197466</PMID>
  </reference>
  <reference>
    <citation>Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998 Feb;155(2):264-71. Erratum in: Am J Psychiatry 1998 Apr;155(4):578.</citation>
    <PMID>9464208</PMID>
  </reference>
  <reference>
    <citation>Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, Kanter ME, Chapman F, Zabriskie J. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry. 1997 Jan;154(1):110-2.</citation>
    <PMID>8988969</PMID>
  </reference>
  <reference>
    <citation>Tan J, Smith CH, Goldman RD. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Can Fam Physician. 2012 Sep;58(9):957-9.</citation>
    <PMID>22972724</PMID>
  </reference>
  <reference>
    <citation>Vincenzi B, O'Toole J, Lask B. PANDAS and anorexia nervosa--a spotters' guide: suggestions for medical assessment. Eur Eat Disord Rev. 2010 Mar;18(2):116-23. doi: 10.1002/erv.977. Review.</citation>
    <PMID>20148396</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Susanne Bejerot</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

